Sydney Lupkin
From this contributor
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Eight pharmaceutical companies more than doubled their lobbying spending in the first three months of 2017.
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Health companies gave generously to President Trump’s inauguration
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events.
Health companies gave generously to President Trump’s inauguration
Trump’s choice to run food and drug agency has pharma connections
Scott Gottlieb, nominated to lead the U.S. Food and Drug Administration has deep ties to industry, and has worn many other hats in his career.
Trump’s choice to run food and drug agency has pharma connections
Senators call for investigation into possible abuses of Orphan Drug Act
Building on weeks of mounting pressure to address high prescription drug prices, three influential U.S. senators have asked the government’s accountability arm to probe the orphan drug program for potential misuse.
Senators call for investigation into possible abuses of Orphan Drug Act
Former head of FDA concerned about faster drug approvals
Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration's plans to speed up drug approvals and dramatically reduce regulations at the agency.
Former head of FDA concerned about faster drug approvals
Explore more from The Transmitter
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.